The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis. 1983

W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff

Plasma samples from 44 patients with systemic lupus erythematosus (SLE) and 43 with rheumatoid arthritis (RA) were assayed for C3d, a breakdown product of the third component of complement (C3), which was also measured in parallel. Levels of C3d varied in direct proportion with disease activity in RA, whereas C3 showed little change. Although C3d values also increased with worsening clinical condition in SLE, this trend was not considered to be sufficiently clear to be useful and did not provide any advantage over the routinely performed C3 assay.

UI MeSH Term Description Entries
D008180 Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. Libman-Sacks Disease,Lupus Erythematosus Disseminatus,Systemic Lupus Erythematosus,Disease, Libman-Sacks,Libman Sacks Disease
D003167 Complement Activation The sequential activation of serum COMPLEMENT PROTEINS to create the COMPLEMENT MEMBRANE ATTACK COMPLEX. Factors initiating complement activation include ANTIGEN-ANTIBODY COMPLEXES, microbial ANTIGENS, or cell surface POLYSACCHARIDES. Activation, Complement,Activations, Complement,Complement Activations
D003176 Complement C3 A glycoprotein that is central in both the classical and the alternative pathway of COMPLEMENT ACTIVATION. C3 can be cleaved into COMPLEMENT C3A and COMPLEMENT C3B, spontaneously at low level or by C3 CONVERTASE at high level. The smaller fragment C3a is an ANAPHYLATOXIN and mediator of local inflammatory process. The larger fragment C3b binds with C3 convertase to form C5 convertase. C3 Complement,C3 Precursor,Complement 3,Complement C3 Precursor,Complement Component 3,Precursor-Complement 3,Pro-C3,Pro-Complement 3,C3 Precursor, Complement,C3, Complement,Complement, C3,Component 3, Complement,Precursor Complement 3,Precursor, C3,Precursor, Complement C3,Pro C3,Pro Complement 3
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis
D015933 Complement C3d A 302-amino-acid fragment in the alpha chain (672-1663) of C3b. It is generated when C3b is inactivated (iC3b) and its alpha chain is cleaved by COMPLEMENT FACTOR I into C3c, and C3dg (955-1303) in the presence COMPLEMENT FACTOR H. Serum proteases further degrade C3dg into C3d (1002-1303) and C3g (955-1001). C3d Complement,Complement 3d,Complement C3d Fragment,Complement Component 3d,C3d Fragment, Complement,C3d, Complement,Complement, C3d,Component 3d, Complement,Fragment, Complement C3d

Related Publications

W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
March 2010, Arthritis and rheumatism,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
January 1970, Naika. Internal medicine,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
March 1958, Annals of the rheumatic diseases,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
December 2007, The New England journal of medicine,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
January 1976, Journal of clinical pathology,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
September 1973, Proceedings of the Royal Society of Medicine,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
January 1981, Ryumachi. [Rheumatism],
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
January 2009, Bulletin of the NYU hospital for joint diseases,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
August 1969, The Australian & New Zealand journal of obstetrics & gynaecology,
W J Morrow, and D J Williams, and C Ferec, and R Casburn-Budd, and D A Isenberg, and E Paice, and M L Snaith, and P Youinou, and P Le Goff
January 2008, Clinical and experimental rheumatology,
Copied contents to your clipboard!